Literature DB >> 31076188

Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis.

Miquel Bioque1, Sergi Mas2, Maria Cristina Costanzo3, Bibiana Cabrera4, Antonio Lobo5, Ana González-Pinto6, Elisa Rodriguez-Toscano7, Iluminada Corripio8, Eduard Vieta9, Immaculada Baeza10, Ángela Ibáñez11, Miguel Gutiérrez Fraile12, Manuel J Cuesta13, Gisela Mezquida14, Amalia Lafuente15, Miguel Bernardo16.   

Abstract

Alterations of the endocannabinoid system (ECS) may play an important role in the development of schizophrenia and other psychotic disorders. Cannabis use is one of the environmental factors more repeatedly related to an increase the risk of developing a psychotic episode, while its use modifies the ECS normal function. In the present study we purposed to examine the gene by environment (GxE) interaction between 15 selected single nucleotide polymorphisms (SNPs) related to the ECS and cannabis use in a cohort of 321 patients with a first episode of psychosis (FEP) and 241 matched healthy controls. We found the fatty-acid amide hydrolase (FAAH) rs2295633 SNP genetic polymorphism was associated with a greater risk of presenting a FEP in subjects with relevant cannabis use, but not in subjects without a history of cannabis use. The probability of presenting a FEP was tenfold higher (OR: 10.69) in cannabis users who were homozygote carriers of the T allele of the FAAH rs2295633 SNP, compared to users of cannabis without this genotype. We also found that a higher a proportion of TT carriers of the FAAH rs2295633 SNP with a positive history of cannabis use was treated with high potency antipsychotic. This study has identified a GxE-environment interaction between a genetic polymorphism from the ECS and cannabis use involved in the risk of presenting a FEP. Although this preliminary data should be replicated with independent samples, our results highlight the importance of the pro-psychotic effects of exogenous cannabis use over the ECS in certain subjects.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Cannabis; Endocannabinoid system; FAAH; Psychosis; Schizophrenia; rs2295633

Mesh:

Substances:

Year:  2019        PMID: 31076188     DOI: 10.1016/j.euroneuro.2019.04.005

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  6 in total

1.  Cognitive Behavioral Therapy Program for Cannabis Use Cessation in First-Episode Psychosis Patients: A 1-Year Randomized Controlled Trial.

Authors:  Itxaso González-Ortega; Enrique Echeburúa; Susana Alberich; Miguel Bernardo; Eduard Vieta; Gonzalo Salazar de Pablo; Ana González-Pinto
Journal:  Int J Environ Res Public Health       Date:  2022-06-15       Impact factor: 4.614

2.  Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use.

Authors:  Daniel Guinart; Estefanía Moreno; Liliana Galindo; Aida Cuenca-Royo; Marta Barrera-Conde; Ezequiel J Pérez; Cristina Fernández-Avilés; Christoph U Correll; Enric I Canela; Vicent Casadó; Arnau Cordomi; Leonardo Pardo; Rafael de la Torre; Víctor Pérez; Patricia Robledo
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

3.  Prodromal phase: Differences in prodromal symptoms, risk factors and markers of vulnerability in first episode mania versus first episode psychosis with onset in late adolescence or adulthood.

Authors:  Norma Verdolini; Roger Borràs; Giulio Sparacino; Marina Garriga; Maria Sagué-Vilavella; Santiago Madero; Roberto Palacios-Garrán; Maria Serra; Maria Florencia Forte; Estela Salagre; Alberto Aedo; Pilar Salgado-Pineda; Irene Montoro Salvatierra; Vanessa Sánchez Gistau; Edith Pomarol-Clotet; Josep Antoni Ramos-Quiroga; Andre F Carvalho; Clemente Garcia-Rizo; Juan Undurraga; María Reinares; Anabel Martinez Aran; Miguel Bernardo; Eduard Vieta; Isabella Pacchiarotti; Silvia Amoretti
Journal:  Acta Psychiatr Scand       Date:  2022-02-25       Impact factor: 7.734

4.  Effects of Cannabis Use on the Protein and Lipid Profile of Olfactory Neuroepithelium Cells from Schizophrenia Patients Studied by Synchrotron-Based FTIR Spectroscopy.

Authors:  Sergi Saladrigas-Manjón; Tanja Dučić; Liliana Galindo; Cristina Fernández-Avilés; Víctor Pérez; Rafael de la Torre; Patricia Robledo
Journal:  Biomolecules       Date:  2020-02-19

Review 5.  Shedding light on the role of CX3CR1 in the pathogenesis of schizophrenia.

Authors:  Katarzyna Chamera; Magdalena Szuster-Głuszczak; Agnieszka Basta-Kaim
Journal:  Pharmacol Rep       Date:  2021-05-22       Impact factor: 3.024

Review 6.  Gene-Environment Interactions in Schizophrenia: A Literature Review.

Authors:  Marah H Wahbeh; Dimitrios Avramopoulos
Journal:  Genes (Basel)       Date:  2021-11-23       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.